Table 2.
Expression of phospho-Src expression in CSCC patients according to clinicopathologic characteristics
| Characteristics | NO. | phospho-Src | p | |
|---|---|---|---|---|
|
| ||||
| Positive N (%) | Negative N (%) | |||
| Age (y) | 0.793 | |||
| ≤40 | 40 | 9 (22.5) | 31 (77.5) | |
| >40 | 47 | 9 (19.1) | 38 (80.9) | |
| FIGO Stage | 0.405 | |||
| IB1 | 30 | 8 (26.7) | 22 (73.3) | |
| >IB1 | 57 | 10 (17.5) | 47 (82.5) | |
| Differentiation | 0.606 | |||
| Grade 1/2 | 39 | 7 (17.9) | 32 (82.1) | |
| Grade 3 | 48 | 11 (22.9) | 37 (77.1) | |
| LN Metastasis | 1.000 | |||
| - | 79 | 17 (21.5) | 62 (78.5) | |
| + | 8 | 1 (12.5) | 7 (87.5) | |
| Recurrence | 0.008 | |||
| - | 79 | 13 (16.5) | 66 (83.5) | |
| + | 8 | 5 (62.5) | 3 (37.5) | |